179 related articles for article (PubMed ID: 34269158)
1. Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis.
Yuan C; Zhang J; Lou J; Wang S; Jiang Y; Wu F; Wang S
Bioengineered; 2021 Dec; 12(1):3850-3863. PubMed ID: 34269158
[TBL] [Abstract][Full Text] [Related]
2. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
3. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
4. The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages.
Tan Z; Xie N; Banerjee S; Cui H; Fu M; Thannickal VJ; Liu G
J Biol Chem; 2015 Jan; 290(1):46-55. PubMed ID: 25406319
[TBL] [Abstract][Full Text] [Related]
5. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.
Baenke F; Dubuis S; Brault C; Weigelt B; Dankworth B; Griffiths B; Jiang M; Mackay A; Saunders B; Spencer-Dene B; Ros S; Stamp G; Reis-Filho JS; Howell M; Zamboni N; Schulze A
J Pathol; 2015 Oct; 237(2):152-65. PubMed ID: 25965974
[TBL] [Abstract][Full Text] [Related]
6. Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells.
Hu X; Liu Z; Duan X; Han X; Yuan M; Liu L; Xia X; Li N; Qin J; Wang Y
Mol Carcinog; 2021 Oct; 60(10):702-714. PubMed ID: 34347919
[TBL] [Abstract][Full Text] [Related]
7. Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets.
Li Z; Wu Q; Sun S; Wu J; Li J; Zhang Y; Wang C; Yuan J; Sun S
Biochem Biophys Res Commun; 2018 Jul; 501(4):962-967. PubMed ID: 29775610
[TBL] [Abstract][Full Text] [Related]
8. Monocarboxylate transporter 4 deficiency enhances high-intensity interval training-induced metabolic adaptations in skeletal muscle.
Tamura Y; Jee E; Kouzaki K; Kotani T; Nakazato K
J Physiol; 2024 Apr; 602(7):1313-1340. PubMed ID: 38513062
[TBL] [Abstract][Full Text] [Related]
9. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments.
Contreras-Baeza Y; Sandoval PY; Alarcón R; Galaz A; Cortés-Molina F; Alegría K; Baeza-Lehnert F; Arce-Molina R; Guequén A; Flores CA; San Martín A; Barros LF
J Biol Chem; 2019 Dec; 294(52):20135-20147. PubMed ID: 31719150
[TBL] [Abstract][Full Text] [Related]
10. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
Gallagher SM; Castorino JJ; Wang D; Philp NJ
Cancer Res; 2007 May; 67(9):4182-9. PubMed ID: 17483329
[TBL] [Abstract][Full Text] [Related]
11. Monocarboxylate Transporter 4 (MCT4) Overexpression Is Correlated with Poor Prognosis of Osteosarcoma.
Liu Y; Sun X; Huo C; Sun C; Zhu J
Med Sci Monit; 2019 Jun; 25():4278-4284. PubMed ID: 31177263
[TBL] [Abstract][Full Text] [Related]
12. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner.
Lim KS; Lim KJ; Price AC; Orr BA; Eberhart CG; Bar EE
Oncogene; 2014 Aug; 33(35):4433-41. PubMed ID: 24077291
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts.
Whitaker-Menezes D; Martinez-Outschoorn UE; Lin Z; Ertel A; Flomenberg N; Witkiewicz AK; Birbe RC; Howell A; Pavlides S; Gandara R; Pestell RG; Sotgia F; Philp NJ; Lisanti MP
Cell Cycle; 2011 Jun; 10(11):1772-83. PubMed ID: 21558814
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
16. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
[TBL] [Abstract][Full Text] [Related]
18. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
Baek G; Tse YF; Hu Z; Cox D; Buboltz N; McCue P; Yeo CJ; White MA; DeBerardinis RJ; Knudsen ES; Witkiewicz AK
Cell Rep; 2014 Dec; 9(6):2233-49. PubMed ID: 25497091
[TBL] [Abstract][Full Text] [Related]
19. MCT4 and CD147 colocalize with MMP14 in invadopodia and support matrix degradation and invasion by breast cancer cells.
Meng S; Sørensen EE; Ponniah M; Thorlacius-Ussing J; Crouigneau R; Larsen T; Borre MT; Willumsen N; Flinck M; Pedersen SF
J Cell Sci; 2024 Apr; 137(8):. PubMed ID: 38661040
[TBL] [Abstract][Full Text] [Related]
20. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
Fang Y; Liu W; Tang Z; Ji X; Zhou Y; Song S; Tian M; Tao C; Huang R; Zhu G; Jiang X; Gao J; Qu W; Wang H; Zhou P; Wu X; Jin L; Sun H; Ding Z; Peng Y; Zhao S; Zhou J; Fan J; Xu W; Shi Y
Hepatology; 2023 Jan; 77(1):109-123. PubMed ID: 35043976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
